Market closedNon-fractional
Adaptive Biotechnologies/ADPT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Adaptive Biotechnologies
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).
Ticker
ADPT
Sector
Healthcare
Trading on
NASDAQ
Industry
Life Sciences Tools and Services
Headquarters
Seattle, United States
Employees
709
Website
www.adaptivebiotech.com
ADPT Metrics
BasicAdvanced
$638M
Market cap
-
P/E ratio
-$1.48
EPS
1.34
Beta
-
Dividend rate
Price and volume
Market cap
$638M
Beta
1.34
Financial strength
Current ratio
4.509
Quick ratio
4.243
Long term debt to equity
79.502
Total debt to equity
82.994
Interest coverage (TTM)
-14.57%
Management effectiveness
Return on assets (TTM)
-17.10%
Return on equity (TTM)
-61.58%
Valuation
Price to revenue (TTM)
3.597
Price to book
2.33
Price to tangible book (TTM)
4.23
Price to free cash flow (TTM)
-4.334
Growth
Revenue change (TTM)
-5.33%
Earnings per share change (TTM)
8.69%
3-year revenue growth (CAGR)
14.61%
3-year earnings per share growth (CAGR)
8.66%
What the Analysts think about ADPT
Analyst Ratings
Majority rating from 8 analysts.
ADPT Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$42M
-8.53%
Net income
-$48M
-31.56%
Profit margin
-113.63%
-25.17%
ADPT Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.33
-$0.35
-$0.48
-$0.33
-
Expected
-$0.35
-$0.34
-$0.33
-$0.34
-$0.33
Surprise
-4.79%
3.28%
44.91%
-3.35%
-
ADPT News
AllArticlesVideos
Adaptive Biotechnologies to Report Second Quarter 2024 Financial Results on August 1, 2024
GlobeNewsWire·2 weeks ago
Adaptive Biotechnologies Announces Data Supporting the Clinical Benefits of MRD Assessment with clonoSEQ® To Be Presented at the Upcoming 2024 ASCO Annual Meeting and EHA2024 Hybrid Congress
GlobeNewsWire·2 months ago
Adaptive Biotechnologies to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Adaptive Biotechnologies stock?
Adaptive Biotechnologies (ADPT) has a market cap of $638M as of July 27, 2024.
What is the P/E ratio for Adaptive Biotechnologies stock?
The price to earnings (P/E) ratio for Adaptive Biotechnologies (ADPT) stock is 0 as of July 27, 2024.
Does Adaptive Biotechnologies stock pay dividends?
No, Adaptive Biotechnologies (ADPT) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Adaptive Biotechnologies dividend payment date?
Adaptive Biotechnologies (ADPT) stock does not pay dividends to its shareholders.
What is the beta indicator for Adaptive Biotechnologies?
Adaptive Biotechnologies (ADPT) has a beta rating of 1.34. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Adaptive Biotechnologies stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.